BlossomHill Therapeutics
- Market cap
- 527.95M
- P/E (TTM)i
- -6.80
- P/Bi
- -3.02
- EPSi
- -3.69
- Div yieldi
- 0.00%
- 52W posi
- 11%
Anonymous reader poll. Unscientific, not investment advice.
BlossomHill Therapeutics ended the session at 16.61, down 3.93%. The company carries a market value of roughly 527.95M, the #3711 most valuable US-listed company we track. Across 5 analysts the consensus rating is Buy, with an average price target of 35.40 (+113%). The shares sit 11% of the way up their 52-week range of 15.25 to 27.99.
✦ StockVane Quant Insights how this is computed
- Main-fund capital flow has been a net outflow over the last 43 sessions.
- Analyst tilt is Buy.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Price chart
Key statistics
Price & volume
- Prev close
- 17.29
- Open
- 17.17
- Day range
- 16.12 - 17.67
- Avg price
- 16.61
- Volume
- 253.81K
- Turnover
- 4.22M
- Turnover ratei
- 2.71%
- Volume ratioi
- 1.11
- Amplitudei
- 8.98%
- 52-week rangei
- 15.25 - 27.99
Valuation
- P/Ei
- -4.50
- P/E (TTM)i
- -6.80
- P/Bi
- -3.02
- EPSi
- -3.69
- Book value / shi
- -5.50
- Net profit
- -117.29M
- Net assets
- -174.79M
Share structure
- Market cap
- 527.95M
- Float capi
- 155.72M
- Shares out
- 31.78M
- Float sharesi
- 9.38M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2026-08-07
40.7% below the 52-week high
Trading activity
Net capital flow main funds, last 43 sessions
-396.72K net over the window
Short interest
- Shares short
- 137.57K
- % of floati
- 0.45%
- Days to coveri
- 1.00
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of BlossomHill Therapeutics (BLSM)?
BlossomHill Therapeutics last traded at 16.61. The quote on this page refreshes every few seconds while US markets are open.
What is BlossomHill Therapeutics's market cap?
About 527.95M.
What is the P/E ratio of BlossomHill Therapeutics?
The trailing twelve-month P/E is -6.80. The Valuation tab shows it against the stock's own five-year range.
Does BlossomHill Therapeutics pay a dividend?
BlossomHill Therapeutics does not currently pay a regular dividend.
Is BlossomHill Therapeutics a buy according to analysts?
The consensus of 5 analysts is a Buy rating, with an average 12-month price target of 35.40, which implies 113.1% upside from the current price. This is not investment advice.
Quote time 2026-10-08 04:52:37 · For reference only, not investment advice and not tailored to your situation.